Business / Finance

RSS

Meda signs agreement to acquire MidNite OTC sleep-aid product

Meda has signed an agreement to acquire MidNite, an OTC sleep-aid product. MidNite is well established in the U.S. and holds a market leading position within a growing category. Annualized revenues for MidNite are approximately 100 MSEK.

7 Dec 2012

RedHill Biopharma completes $6.5M private placement

RedHill Biopharma Ltd., an Israeli biopharmaceutical company focusing primarily on development and acquisition of late clinical stage, patent-protected, new formulations and combinations of existing drugs, reported the completion of a private placement in a total amount of approximately $6.5 million.

6 Dec 2012

IASIS Healthcare fourth quarter net revenue decreases 2.2% to $633.0 million

IASIS Healthcare LLC, today announced financial and operating results for the fiscal fourth quarter and year ended September 30, 2012.

6 Dec 2012

Using Nanoparticles to Target Cancer

An interview with John Stroh, discussing the development of nanoparticles that can target and treat cancer, without damaging nearby tissues.

6 Dec 2012

Moderna Therapeutics closes $40M in financing

Moderna Therapeutics announced today that it has closed more than $40 million in financing to date, led by Flagship Ventures and private investors, which will be used to advance multiple programs toward clinical stage development.

6 Dec 2012

Biomatrica completes $5 million in private financing

Biomatrica, Inc., a leader in ambient temperature biostability technology, today announced the completion of $5 million in private financing. Biomatrica has developed SampleMatrix technology which has pioneered recent innovations in ambient storage of biological samples, from purified DNA, RNA, and proteins to complex systems such as tissue, cell lines, biopsies and whole blood.

6 Dec 2012

Air Medical Group acquires REACH

REACH Medical Holdings LLC, parent company of REACH Air Medical Services with headquarters in Santa Rosa, has been wholly acquired by Air Medical Group Holdings, Inc. (AMGH).

6 Dec 2012

Baxter enters definitive agreement to acquire Gambro

Baxter International Inc. has entered into a definitive agreement to acquire Gambro AB, a privately held dialysis product company based in Lund, Sweden, for total consideration of 26.5 billion SEK (approximately $4.0 billion USD at current exchange rates).

From Baxter International Inc. 5 Dec 2012

Kona Medical completes Series C financing

Kona Medical, Inc. today announced it has completed its Series C financing with the addition of $10 million in equity and debt, bringing total proceeds to $40 million.

4 Dec 2012

Flexion raises $20M in Series B financing round

Flexion Therapeutics, Inc. today announced that the company has secured $20 million in a Series B financing round led by new investor, Novo Ventures.

4 Dec 2012

DaVita acquires Tulips Dialysis Centre; opens two new joint venture centers in Malaysia

DaVita, a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD), today announced the acquisition of Tulips Dialysis Centre and has opened two new joint venture centers in Malaysia.

3 Dec 2012

HCA Holdings proposes to offer $1.0 billion senior notes

HCA Holdings, Inc. today announced that it proposes to offer, subject to market and other considerations, $1.0 billion aggregate principal amount of senior notes. Actual terms of the notes, including interest rate and principal amount, will depend on market conditions at the time of pricing.

3 Dec 2012

BVM Capital makes seed round investment in Fitness Interactive Experience

BVM Capital today announced that it has made a seed round investment in health and fitness gaming innovator Fitness Interactive Experience (FIX). FIX is dedicated to helping people achieve enhanced levels of fitness and health by making fitness fun, accessible and socially connected through harnessing the power of massively multiplayer on-line games. FIX is developing an interactive social media platform designed to make the pursuit of fitness an engaging and enjoyable game.

3 Dec 2012

Chromadex completes acquisition of Spherix Consulting

ChromaDex Corporation ("ChromaDex"), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, animal health, cosmetic and pharmaceutical industries, and marketer of its branded, patented pterostilbene, pTeroPure®, announced today the completion of the acquisition of Spherix Consulting, Inc., a subsidiary of Spherix, Inc.

3 Dec 2012

Pfizer sells Nutrition business to Nestlé for $11.85 billion

Pfizer Inc. announced today that it has completed the sale of its Nutrition business to Nestlé for $11.85 billion in cash, following the conclusion of the required regulatory process in most markets. In certain countries where completion will be delayed due to ongoing regulatory review, Pfizer will continue to operate the business on an interim basis.

30 Nov 2012

CACI completes transaction to acquire Emergint Technologies

CACI International Inc. announced today that it has completed its transaction to acquire Emergint Technologies, Inc., a premier provider of emerging technology solutions focused on the data-driven needs of national health organizations. This acquisition builds on CACI's healthcare IT capability and expands its presence in the growing healthcare IT market.

30 Nov 2012

HIV travel bans violate human rights, hurt business

Writing in the Huffington Post's "Impact" blog, Chip Bergh, president and CEO of Levi Strauss & Co., and Kenneth Cole, CEO of Kenneth Cole Productions and chair of the Board of amfAR, The Foundation for AIDS Research, discuss why some CEOs oppose HIV travel bans.

30 Nov 2012

EHS reports addition of 78,000 new members to Central Valley operations

EHS Medical Group reported today the addition of 78,000 new members to their Central Valley operations. The growth makes Central Valley the company's single largest region by membership outside of Los Angeles County.

30 Nov 2012

Pivotal Therapeutics reports loss of $811,164 for third quarter 2012

Pivotal Therapeutics Inc., a specialty pharmaceutical company with a focus on cardiovascular disease and overall health today announced its financial results and operational highlights for the quarter ended September 30, 2012. All dollar amounts referenced herein are in Canadian dollars unless otherwise stated.

30 Nov 2012

ArmaGen closes $17M Series A financing

ArmaGen Technologies, Inc. today announced the closing of a $17 million Series A financing to support the development of brain-penetrating recombinant protein therapeutics.

29 Nov 2012